Expanding Local Cancer Clinical Trial Options: Analysis of the Economic Impact of the Midwest Cancer Alliance in Kansas.

Acad Med

J.A. Gafford is a PhD student, Department of Health Policy and Management, University of Kansas School of Medicine, Kansas City, Kansas. T. Gurley-Calvez is associate professor, Department of Health Policy and Management, University of Kansas School of Medicine, Kansas City, Kansas. H. Krebill is executive director, Midwest Cancer Alliance, Kansas City, Kansas. S.M. Lai is professor, Preventive Medicine and Public Health, and director, Kansas Cancer Registry, University of Kansas School of Medicine, Kansas City, Kansas. Christiadi is research associate/demographer, Bureau of Business and Economic Research, West Virginia University, Morgantown, West Virginia. G.C. Doolittle is Capital Federal Masonic Professor, Medical Oncology, and medical director, Center for Telemedicine and Telehealth, University of Kansas School of Medicine, as well as medical director, Midwest Cancer Alliance, Kansas City, Kansas.

Published: September 2017

Purpose: Patients benefit from receiving cancer treatment closer to home when possible and at high-volume regional centers when specialized care is required. The purpose of this analysis was to estimate the economic impact of retaining more patients in-state for cancer clinical trials and care, which might offset some of the costs of establishing broader cancer trial and treatment networks.

Method: Kansas Cancer Registry data were used to estimate the number of patients retained in-state for cancer care following the expansion of local cancer clinical trial options through the Midwest Cancer Alliance based at the University of Kansas Medical Center. The 2014 economic impact of this enhanced local clinical trial network was estimated in four parts: Medical spending was estimated on the basis of National Cancer Institute cost-of-care estimates. Household travel cost savings were estimated as the difference between in-state and out-of-state travel costs. Trial-related grant income was calculated from administrative records. Indirect and induced economic benefits to the state were estimated using an economic impact model.

Results: The authors estimated that the enhanced local cancer clinical trial network resulted in approximately $6.9 million in additional economic activity in the state in 2014, or $362,000 per patient retained in-state. This estimate includes $3.6 million in direct spending and $3.3 million in indirect economic activity. The enhanced trial network also resulted in 45 additional jobs.

Conclusions: Retaining patients in-state for cancer care and clinical trial participation allows patients to remain closer to home for care and enhances the state economy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574436PMC
http://dx.doi.org/10.1097/ACM.0000000000001612DOI Listing

Publication Analysis

Top Keywords

clinical trial
20
cancer clinical
16
economic impact
16
cancer
12
local cancer
12
in-state cancer
12
trial network
12
trial options
8
midwest cancer
8
cancer alliance
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!